Ardelyx (ARDX) Depreciation & Amortization (CF) (2013 - 2026)
Ardelyx (ARDX) posted Depreciation & Amortization (CF) of $915000.0 for Q1 2026, down 0.65% on a QoQ basis from $921000.0 in Q4 2025, and up 51.99% year-over-year from $602000.0 in Q1 2025.
Ardelyx (ARDX) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Ardelyx's Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $915000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 51.99% year-over-year to $915000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 51.21% YoY) and the FY2025 annual result came in at $3.1 million, up 48.28% from the prior year.
- Depreciation & Amortization (CF) was $915000.0 for Q1 2026 at Ardelyx, down from $921000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $921000.0 in Q4 2025 and bottomed at -$3000.0 in Q1 2023.
- A 5-year average of $498411.8 and a median of $515000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) tumbled 100.65% — and 2024, when it soared 14600.0%.
- Ardelyx's Depreciation & Amortization (CF) stood at $127000.0 in 2022, then surged by 185.04% to $362000.0 in 2023, then jumped by 42.27% to $515000.0 in 2024, then surged by 78.83% to $921000.0 in 2025, then retreated by 0.65% to $915000.0 in 2026.
- Business Quant data shows ARDX's Depreciation & Amortization (CF) at $915000.0 in Q1 2026, $921000.0 in Q4 2025, and $905000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Ardelyx | 1.24 Bn | 999.81 Mn | 89.66 Mn | 915,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 915,000.00 |
| Mar 31, 2026 | 915,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Jun 30, 2025 | 631,000.00 |
| Jun 30, 2025 | 631,000.00 |
| Mar 31, 2025 | 602,000.00 |
| Mar 31, 2025 | 602,000.00 |
| Dec 31, 2024 | 515,000.00 |
| Dec 31, 2024 | 515,000.00 |
| Sep 30, 2024 | 544,000.00 |
| Sep 30, 2024 | 544,000.00 |
| Jun 30, 2024 | 569,000.00 |
| Jun 30, 2024 | 569,000.00 |
| Mar 31, 2024 | 435,000.00 |
| Mar 31, 2024 | 435,000.00 |
| Dec 31, 2023 | 362,000.00 |
| Dec 31, 2023 | 362,000.00 |